IMPROVE

  • Search

Search

  • About
    • Our team
    • Secretariat
    • Partners and Collaborators
    • Contact us
  • Projects
    • IMPROVE Trial
    • IMPROVE-2 Trial
    • Molecular markers of antimalarial resistance
    • Antimicrobial activity and the impact of drug resistance
    • Acceptability, feasibility and health economics
    • Capacity development
The IMPROVE Consortium was established to evaluate whether intermittent preventive therapy (IPTp) with dihydroartemisinin-piperaquine (DP), with or without azithromycin (AZ), is a viable alternative to current policy for the prevention of malaria and sexually transmitted and reproductive tract infections (STIs/RTIs) in pregnancy in high SP resistance areas in Kenya, Malawi, and Tanzania.  
The Consortium comprises two multicentre trials, one conducted among HIV-uninfected women (IMPROVE) and one among HIV-infected women taking co-trimoxazole (IMPROVE-2).  
0

Research Themes

Piperaquine and dolutegravir drug-drug interactions study in pregnant women

IMPROVE Trial

IMPROVE-2 Trial

Molecular markers of antimalarial resistance

Antimicrobial activity and the impact of drug resistance

Acceptability, feasibility and health economics

Capacity development

Who we are

About and Welcome

Secretariat

Partners

Collaborators

Principle Investigators

Professor Feiko ter Kuile

Chief Investigator

Dr Mwayiwawo Madanitsa

IMPROVE Trial Manager

Dr Hellen Barsosio

IMPROVE 2 Trial Manager

Dr Jenny Hill

Associate Professor, Michael Alifrangis

Dr Simon Kariuki

Professor Frank Mosha

Associate Professor, Matthew Chico

Professor John Lusingu

Professor Bjarne Robberstad

Professor Jayne Webster

Professor Kara Hanson

Professor Victor Mwapasa

Contact us

Liverpool School of Tropical Medicine
Pembroke Place
Liverpool
L3 5QA
Tracy Seddon, Programme Coordinator
Email: tracy [dot] seddon [at] lstmed [dot] ac [dot] uk
Tel: +44 (0)151 705 3717

A Remora website by Manta Ray Media